Weight Loss Drugs: What Do We Need to Know?
Weight Loss Drugs: What Do We Need to Know?
Nov. 1, 2024
We're seeing a LOT more medications like Ozempic in the emergency department nowadays. In fact, 12% of U.S. adults have used a GLP-1 drug! So, what do we need to know about these drugs? Dr. Megan Boysen Osborn, Professor of Emergency Medicine at the University of California Irvine, discusses these GLP-1 agonists with host Maiya Smith.
Host
Maiya Smith, MD
University of Utah
Emergency Medicine Residency Class of 2025
@Maiyaandtheadventuremutts
EMRA*Cast Episodes
OVERVIEW
We're seeing a LOT more medications like Ozempic in the emergency department nowadays. In fact, 12% of US adults have used a GLP-1 drug! So, what do we need to know about these drugs? Dr. Megan Boysen Osborn, Professor of Emergency Medicine at the University of California Irvine, discusses these GLP-1 agonists with host Maiya Smith.
TAKE-HOME POINTS
- Obesity is a disease requiring long-term treatment.
- GLP-1 receptor agonists offer a non-surgical option for achieving weight loss goals.
- Side effects of GLP-1 receptor agonists are mainly GI.
References
- Long B, Pelletier J, Koyfman A, Bridwell RE. GLP-1 Agonists: A Review for Emergency Clinicians. Am J Emerg Med. 2024;78:89-94.
- Das SR, Everett BM, Birtcher KK, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(9):1117-1145.
- Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes - State-of-the-Art. Molecular Metabolism. Mol Metab. 2021;46:101102.
- Oppert JM, Ciangura C, Bellicha A. Physical Activity and Exercise for Weight Loss and Maintenance in People Living With Obesity. Rev Endocr Metab Disord. 2023;24(5):937-949.
